A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell
product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with
metastatic melanoma who are not responding or have progressed after receiving prior therapy
with a PD-1/PD-L1 antagonist used alone or in combination with anti-CTLA-4. Additionally, a
second cohort of patients with metastatic melanoma who are not responding or have progressed
after receiving prior therapy with a PD-1/PD-L1 antagonist alone or in combination with
anti-CTLA-4 will receive anti-PD-1 and anti-CTLA-4 therapy with Nivolumab and Ipilimumab.